Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Apr 24, 2012

Life Technologies Pledges $20M to Expand Cell Culture Capacity at Scottish Site

  • Life Technologies will invest $20 million into the construction of a new cell culture facility at its existing manufacturing site in Scotland. The firm says the expansion will support increasing demand for its Gibco® cell culture products for biological drug research, development, and production, and will secure the supply chain for Europe, the Americas, and Asia.  

    The investment is accompanied by ongoing support form Scotland’s development agency, Scottish Enterprise, and will increase Life’s global manufacturing network for its Advanced Granulated Technology (AGT™) and dry powder media under the Gibco brand. “Our investment in this facility now provides a secure, complementary supply chain source for media used in life-saving therapeutics while also addressing the growing global demand for our cell culture media products,” states Gregory T. Lucier, Life Technologies’ chairman and CEO.

    Life already employs 500 people at the Inchinnan site near Glasgow, which is its headquarters for Europe, Africa, and the Middle East. The firm says AGT media is the fastest-growing segment in the Gibco cell culture portfolio. 



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »